Coming off GLP-1. The protocol most clinics skip.

The STEP 4 trial showed that patients who discontinue semaglutide regain two-thirds of their lost weight within a year without a structured exit protocol. Most GLP-1 prescribers have no exit strategy. This note is that strategy.

I. What the discontinuation data shows.

The STEP 4 trial is the most direct evidence available. Rubino et al. enrolled adults who had completed 20 weeks of once-weekly subcutaneous semaglutide and then randomized them to continued semaglutide versus placebo. Those who discontinued regained approximately 6.9% of body weight by week 68 of the trial. Those who continued lost an additional 7.9%. The divergence is not subtle. verified [I]

Observational follow-up extended the picture further: at one year post-discontinuation, the majority of weight that had been lost was regained. The SURMOUNT-4 data with tirzepatide shows a parallel pattern. Patients who completed an open-label tirzepatide lead-in and were then randomized to placebo regained substantial weight relative to those who continued active treatment. The drug class carries the same discontinuation liability regardless of which receptor it targets. verified [I]

The mechanism is pharmacological, not behavioral. GLP-1 receptor agonists reduce appetite via central and peripheral pathways: slowing gastric emptying, signaling satiety to the hypothalamus, and suppressing the ghrelin-driven hunger signal. These effects are present as long as the drug is present. Upon discontinuation, the pharmacological appetite suppression resolves within weeks. The biological weight set-point, which has not been durably reset by drug alone, reasserts itself and drives rebound. verified [III]

II. Who is a candidate for GLP-1 discontinuation.

Not every patient on a GLP-1 agonist is a candidate for discontinuation at every point in their course. Four conditions constitute the minimum threshold for a reasonable exit attempt.

Metabolic normalization. HOMA-IR below 1.5, HbA1c below 5.4%, and fasting insulin below 5 mU/L. These values indicate that the underlying metabolic driver of weight gain has been at least partially addressed. A patient who has lost weight on semaglutide but still carries a HOMA-IR of 3.5 has not resolved the insulin resistance that made weight gain easy and weight loss difficult. Discontinuing in that state is removing the scaffolding before the structure can stand alone.

Lean mass preservation, DEXA-confirmed. This is the critical prerequisite that most clinics omit entirely. A patient who lost 30 lbs on a GLP-1 agonist but lost 10 lbs of that as muscle has a worse metabolic platform than before starting. Muscle tissue is the primary site of insulin-stimulated glucose disposal. Loss of lean mass worsens insulin sensitivity and reduces resting energy expenditure: the two factors that make weight maintenance hardest. Do not attempt a GLP-1 exit without a current DEXA showing preserved or improved lean mass.

Resistance training established. The patient must be performing 3 to 4 sessions per week with progressive overload. This is the non-negotiable behavioral anchor for weight maintenance post-discontinuation. No resistance training program means no durable metabolic substrate for the exit to land on.

Protein floor established. 1.6 to 2.2 g per kg of lean body mass per day, consistent, verified by food log or dietary consult. Protein adequacy drives lean mass retention and supports the satiety signaling that GLP-1 was previously augmenting pharmacologically.

If any of these conditions are not met, the exit attempt will likely fail. Address the deficiency first. The taper protocol below applies only to patients who meet all four criteria.

III. The taper protocol.

Abrupt discontinuation maximizes rebound. The taper serves a specific physiological purpose: it allows gradual re-adaptation of GLP-1 receptor expression and central appetite circuitry, reducing the severity of the hunger signal that returns when pharmacological suppression is removed. Eight to sixteen weeks is the target range depending on maintenance dose and patient history.

Semaglutide taper example. If the patient is at a maintenance dose of 1.0 mg or 2.4 mg weekly: reduce to 0.5 mg weekly for 4 weeks, then to 0.25 mg weekly for 4 weeks, then discontinue. Patients who were at lower maintenance doses can shorten the taper proportionally.

Tirzepatide taper. Reduce by one dose step every 4 weeks. At 10 mg per week: step to 7.5 mg for 4 weeks, then 5 mg for 4 weeks, then 2.5 mg for 4 weeks, then stop. The extended taper for tirzepatide reflects its dual GIP and GLP-1 mechanism and the greater appetite suppression at higher doses.

Monitor weekly weight, appetite self-report using a validated hunger scale (Hunger and Satiety Questionnaire or equivalent), fasting glucose, and fasting insulin every 4 weeks throughout the taper. Any upward trend in fasting insulin above 8 mU/L during the taper is a signal to slow the taper rate, not to abandon the exit.

IV. The exit stack.

During and after the taper, the following compounds support metabolic stability and weight maintenance as GLP-1 pharmacological support withdraws. These are adjuncts to the behavioral and dietary framework, not substitutes for it.

MOTS-c. AMPK activation is the central mechanism here. MOTS-c drives mitochondrial AMPK signaling, which maintains insulin sensitivity and metabolic flexibility independent of GLP-1 receptor activity. As the drug's contribution to glucose regulation recedes, MOTS-c supports the metabolic platform built during the GLP-1 course. verified

Thymosin alpha-1. GLP-1 receptor agonists have documented immunomodulatory effects at the gut and systemic level. Discontinuation creates a brief immune adjustment period. Thymosin alpha-1 supports regulatory T-cell function and immune calibration during this transition. inferred from mechanism

BPC-157. GLP-1 significantly slows gastric emptying throughout the course of treatment. Discontinuation can produce a period of rebound rapid gastric emptying: nausea, urgency, and altered gut motility as the gut adjusts to the absence of pharmacological slowing. BPC-157 modulates gut motility via VIP and nitric oxide pathways and supports mucosal integrity during the transition. verified

NAD+ precursors. Nicotinamide riboside or NMN at standard clinical doses. Metabolic resilience support during the transition; supports mitochondrial function and SIRT1/SIRT3 activity that underlies long-term insulin sensitivity. inferred from mechanism

V. Appetite management post-discontinuation.

Hunger is the primary risk factor for weight regain after GLP-1 discontinuation. Without pharmacological appetite suppression, the hunger signal returns. The return is not gradual in all patients: some experience a sharp increase in appetite within 2 to 3 weeks of the final dose. Having a structured response to that signal is the difference between a successful exit and a rapid regain trajectory.

Meal structure. Maintain the meal timing pattern established on GLP-1. Smaller, more frequent meals were natural during treatment because gastric emptying was slowed and satiety came earlier. That structure remains beneficial post-discontinuation even as gastric emptying normalizes. Disrupting it is one of the fastest ways to allow opportunistic overconsumption.

Food quality priorities. Continue prioritizing high-volume, high-satiety foods: lean protein, fiber-dense vegetables, whole legumes. Avoid re-introducing ultra-processed foods during the first 6 months post-discontinuation. Ultra-processed foods are engineered to defeat satiety signaling. That signaling is already operating without pharmacological augmentation. This is the worst time to stress-test it.

Berberine, 1000 to 1500 mg per day. Berberine activates AMPK, produces modest improvements in insulin sensitivity, and has emerging evidence as a weak GLP-1 secretagogue: it stimulates endogenous GLP-1 release from intestinal L-cells. It is not a pharmaceutical GLP-1 agonist. It does not replicate the magnitude of appetite suppression. It is, however, a rational and evidence-supported metabolic bridge for the 6-month post-discontinuation window. verified

VI. The monitoring protocol post-discontinuation.

The exit is not complete at the last dose. It is complete at 6 months of maintained metabolic health without pharmacological support. The monitoring schedule below maps to that definition.

Weeks 1 to 4. Weekly weight check-in. Daily protein tracking, self-reported. Subjective hunger rating on a consistent scale, logged at the same time each day. This is the highest-risk window. Weight should remain flat or decline slightly. Hunger will peak in this window and then stabilize. If it does not stabilize, the behavioral and dietary anchors need reinforcement before proceeding.

Months 1 to 3. HOMA-IR and fasting insulin monthly. Body composition monthly via bioelectrical impedance at minimum. Any upward trend in HOMA-IR above 2.0 or any loss of lean mass is a decision point: evaluate for re-initiation at lowest dose, intensification of resistance training, or alternative metabolic intervention.

Month 3. DEXA scan if available. This is the first objective lean mass assessment post-discontinuation. If lean mass is declining relative to the end-of-treatment DEXA: the exit is not succeeding on the body composition axis even if weight appears stable. Address this before month 6.

Month 6. Comprehensive reassessment. Metabolic panel, HOMA-IR, fasting insulin, lipid panel, body composition. If metabolic markers remain stable and body composition is maintained: the exit is successful. Document the outcome and continue annual monitoring. This is the benchmark. If the patient reaches month 6 with maintained lean mass, stable insulin sensitivity, and no weight regain, the GLP-1 course achieved its purpose. That is a clinical success worth documenting.

THE PIVOTAL PROTOCOL is an intelligence and education layer, not a prescriber. The mechanisms and protocols described here are derived from the cited literature and from Pivotal's own protocol design history. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.